BiPar Begins Phase 2 Study Of Lead PARP Inhibitor In Triple-Negative Breast Cancer Based On Overexpression Biomarker Data

BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, announced it has initiated a Phase 2 study of its lead PARP inhibitor, BSI-201, in patients with triple-negative breast cancer that do not express the estrogen, progesterone or HER2 receptors. [click link for full article]

More: continued here

Filed under: Breast Cancer on November 18th, 2007